drugset / Trial / NCT00046319
Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine if treating patients suffering from moderate to severe pulmonary arterial hypertension with BSF 208075 will improve the patients' ability to exercise.
Timeline
- Start
- 2002-09
- Primary completion
- —
- Completion
- 2003-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ambrisentan | Small molecule | 1 mg | Oral |
| Subject | Ambrisentan | Small molecule | 2.5 mg | Oral |
| Subject | Ambrisentan | Small molecule | 5 mg | Oral |
| Subject | Ambrisentan | Small molecule | 10 mg | Oral |